US20110165242A1 - In situ gelling drug delivery system - Google Patents

In situ gelling drug delivery system Download PDF

Info

Publication number
US20110165242A1
US20110165242A1 US12/870,616 US87061610A US2011165242A1 US 20110165242 A1 US20110165242 A1 US 20110165242A1 US 87061610 A US87061610 A US 87061610A US 2011165242 A1 US2011165242 A1 US 2011165242A1
Authority
US
United States
Prior art keywords
drug
plga
peg
composition
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/870,616
Inventor
Dongling Su
Paul Ashton
Jianbing Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals US Inc
Original Assignee
Control Delivery Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Systems Inc filed Critical Control Delivery Systems Inc
Priority to US12/870,616 priority Critical patent/US20110165242A1/en
Assigned to CONTROL DELIVERY SYSTEMS, INC. reassignment CONTROL DELIVERY SYSTEMS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASHTON, PAUL, CHEN, JIANBING, SU, DONGLING
Assigned to PSIVIDA INC. reassignment PSIVIDA INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: CONTROL DELIVERY SYSTEMS, INC.
Publication of US20110165242A1 publication Critical patent/US20110165242A1/en
Assigned to PSIVIDA US, INC. reassignment PSIVIDA US, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PSIVIDA INC.
Priority to US13/612,076 priority patent/US20130101656A1/en
Priority to US14/444,338 priority patent/US9566336B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the field of controlled-release and sustained-release drug delivery systems, and particularly to the field of injectable drug delivery implants.
  • the product can be implanted directly at the site where drug action is needed and hence systemic exposure of the drug can be reduced. This becomes especially important for toxic drugs which are related to various systemic side effects (such as the chemotherapeutic drugs).
  • the polymer matrix protects the drug from the physiological environment, particularly circulating enzymes, thereby improving stability in vivo. This makes the technology particularly attractive for the delivery of labile proteins and peptides.
  • One class of existing implants consists of preformed devices, ranging in size from matchstick-sized cylindrical rods such as the NorplantTM (levonorgestrel) and ZoladexTM (goserelin acetate) implants, to microspheres such as are sold under the trade name Lupron DepotTM (leuprolide acetate).
  • a major disadvantage of the macroscopic devices is their physical size. Implantation of ZoladexTM rods, for instance, requires the use of 14- or 16-gauge needles, and implantation of NorplantTM rods requires a surgical incision under local anesthesia, with similar subsequent procedures to replace and/or remove them. (The ZoladexTM rods are bioerodable, whereas NorplantTM implants are based on a non-bioerodable silicone.) Self-administration of such implants is not feasible, and the required intervention of trained medical personnel greatly raises the cost and inconvenience of such treatments.
  • Drug-containing polymer implants have been reduced in size by the expedient of grinding or milling a mixture of a drug substance and a gel-forming polymer at low temperature, as described in U.S. Pat. No. 5,385,738.
  • the resulting powder is then suspended in a non-aqueous viscous solvent, such polyethylene glycol or a biocompatible oil, to obtain an injectable composition.
  • microsphere implants which can be administered (and self-administered where appropriate) by injection of an aqueous suspension of the microspheres.
  • Lupron DepotTM for example, can be comfortably injected with a 22- or 23-gauge needle.
  • microspheres are not retrievable from the body, they are necessarily based on bioerodable polymers.
  • an aqueous suspension of microspheres is stored for any length of time, the drug will diffuse from the particles into the aqueous phase, furthermore the bioerodable matrix itself is prone to hydrolysis in an aqueous environment.
  • the injectable aqueous suspension must be prepared at the time of injection.
  • a second disadvantage is the need for intramuscular injection.
  • preparation of the microspheres is a complex process that is not easily carried out reproducibly and reliably, and regulatory validation of the manufacturing process can be a significant obstacle to commercialization of such products.
  • Another class of implants differing from pre-formed solid devices is injectable liquids. Upon injection, these are transformed in situ into solid implants.
  • This class of implants is typified by compositions that transform from a drug-containing liquid phase to a drug-infused gel phase upon exposure to a physiological environment.
  • Such in situ gelling compositions have several advantages: they can be readily and reliably manufactured by standard methods, they can be stored in the form of easily-injected liquids, they can be placed locally to achieve local delivery, and they can flow prior to gelling so as to fill voids and create a less-visible subcutaneous implant.
  • a gelling implant can serve as a scaffold for cellular colonization and tissue growth.
  • Temperature-sensitive in situ gelling compositions generally change from a sol to a gel when the temperature exceeds a critical solution temperature, which in the case of drug delivery systems must be reasonably close to body temperature.
  • a critical solution temperature which in the case of drug delivery systems must be reasonably close to body temperature.
  • An example is the polyethylene oxide-polypropylene oxide block copolymer, sold under the trade name PluronicTM F 127.
  • PluronicTM F 127 polyethylene oxide-polypropylene oxide block copolymer
  • a 25-40% aqueous solution of this material will gel at about body temperature, and drug release from such a gel occurs over a period of up to one week.
  • Such compositions have the disadvantage that they must be carefully protected from premature gelling, through refrigerated storage, and no bioerodable polymer has yet been developed that undergoes a sol-gel transition at about body temperature.
  • compositions form gels upon contact with water.
  • GMO glycerol monooleate
  • a drug can be injected as a liquid lamellar phase, which upon injection and exposure to water forms a highly viscous cubic-phase hydrate. The drug is released from the cubic phase over the course of several days.
  • An example of an injectable drug depot product based on GMO is the metronidazole dental gel formulation marketed under the trade name ElyzolTM. Due to the high water content of the cubic phase, GMO formulations are prone to rapid drug release and are limited in duration of effect to no more than about five days.
  • the AtrigelTM drug delivery system consists of a bioerodable poly(DL-lactide-glycolide) (PLGA) copolymer (75:25 molar ratio) dissolved in N-methyl-2-pyrrolidone (NMP). Pharmaceuticals may be blended into this PLGA solution at the point of manufacture, or they may be added by the physician at the time of use.
  • the liquid product is injected subcutaneously or intramuscularly through a small gauge needle, whereupon displacement of the NMP carrier with water in the tissue fluids causes the PLGA to precipitate, forming a solid film or implant.
  • the drug incorporated within the implant is then released in a controlled manner as the polymer matrix erodes with time in the body.
  • PLGA-based implants of this type can release drug over a period of several months.
  • An example of a product employing this technology is the leuprolide acetate formulation marketed under the trade name EligardTM.
  • the AtrigelTM system uses N-methylpyrrolidinone (NMP) as a solvent for the PLGA copolymer.
  • NMP N-methylpyrrolidinone
  • NMP is a water-miscible, low-molecular-weight and low-viscosity solvent that rapidly diffuses from the implant. Rapid solvent escape from the injected composition can lead to rapid and uneven precipitation of the polymer, shrinking of the implant, and local irritation or even necrosis due to exposure of tissues to a high local concentration of solvent.
  • liquid polymers as solvents for in situ gel-forming compositions has been described in U.S. Pat. No. 5,607,686 and in U.S. application Ser. No. 10/169,012 (US 2003/0082234), corresponding to international patent application PCT/KR00/01508 (WO 01/45742).
  • polyethylene glycol is not suitable as a solvent for PLGA.
  • In situ polymer-precipitation systems solve many of the problems associated with implants, but some difficulties remain. There is a need for in situ gelling drug delivery systems with improved properties, a simple preparation procedure and low toxicity of excipient.
  • PEGs have the advantage of solubilizing different drugs than NMP; in particular pegylated proteins can be expected to be more soluble and/or miscible in PEGs than in NMP.
  • An additional advantage is that PEGs are available in different molecular weights and have different viscosities. In many instances it important to be able to control the viscosity of the injected gelling agent, which is not possible with NMP.
  • the morphology of the polymer gel produced during the precipitation process is dependent upon the nature of the organic solvent, which can vary from a dense sponge-like structure to an open meshwork with numerous voids and channels (P. D. Graham et al., J. Controlled Release 58:233-245 (1999)). This morphology in turn affects both the initial burst and the sustained release kinetics of the gel. Solvents used to date for this purpose have largely been selected from the chemist's traditional menu of low-molecular weight species, such as NMP, DMA, alcohols, and the like, as described for example in U.S. Pat. No. 5,780,044.
  • polyethylene glycol can serve as the solvent for PLGA, and have found that the gel phase produced upon exchange of the PEG with water exhibits desirable sustained-release kinetics for small-molecule drugs.
  • the present invention provides an in situ gelling drug delivery formulation comprising a drug substance and a PLGA polymer, dissolved dispersed or suspended in PEG as the liquid phase solvent.
  • the liquid phase solvent may include, or even consist essentially of, a prodrug of the drug substance combined with PEG.
  • the present invention also provides methods for making in situ gelling drug delivery formulations comprising a drug substance and a PLGA polymer, dissolved dispersed or suspended in PEG as the liquid phase solvent.
  • the invention also provides methods for preparing sustained-release drug depots in situ by the use of such formulations.
  • FIG. 1 shows the release profiles for morphine from three different morphine-diclofenac co-drug/PLGA (70:30)/PEG 400 formulations.
  • FIG. 2 shows the release profile for morphine from a morphine-diclofenac co-drug/PLGA (50:50)/PEG 400 formulation (5% w/v PLGA in PEG).
  • FIG. 3 shows the release profile for morphine from a morphine-diclofenac co-drug/PLGA (70:30)/DMA formulation.
  • FIG. 4 shows the release profile for morphine from a morphine-diclofenac co-drug/PLGA (70:30)/benzyl benzoate formulation (20% w/v PLGA in benzyl benzoate).
  • the present invention provides injectable in situ gelling pharmaceutical compositions, comprising: (a) a drug substance; (b) a liquid, semi-solid, or wax polyethylene glycol (PEG); and (c) a biocompatible and bioerodable polymer that is dissolved, dispersed, or suspended in the PEG.
  • a drug substance comprising: (a) a drug substance; (b) a liquid, semi-solid, or wax polyethylene glycol (PEG); and (c) a biocompatible and bioerodable polymer that is dissolved, dispersed, or suspended in the PEG.
  • PEG polyethylene glycol
  • a “liquid” PEG is a polyethylene glycol that is a liquid at 20-30° C. and ambient pressure. In certain preferred embodiments, the average MW of the liquid PEG is between about 200 and about 400.
  • the polyethylene glycol may be linear or it may be a bioabsorbable branched PEG, for example as disclosed in U.S. Patent application No. 2002/0032298.
  • the PEG may be a semi-solid or wax, in which case the M n will be larger, for example 3,000 to 6,000. It will be understood that compositions comprising semi-solid and waxy PEGs may not be amenable to injection, and will accordingly be implanted by alternative means.
  • the drug substance is dissolved in the polyethylene glycol, while in other embodiments the drug substance is dispersed or suspended in the PEG in the form of solid particles.
  • the drug substance may be encapsulated or otherwise incorporated into particles, such as microspheres, nanospheres, liposomes, lipospheres, micelles, and the like, or it may be conjugated to a polymeric carrier. Any such particles are preferably less than about 500 microns in diameter, more preferably less than about 150 microns.
  • the present invention also provides for macroscopic drug delivery devices, for example in the form of hollow particles, capsules or open tubes, which contain an in situ gelling composition of the invention.
  • the devices may be permeable to the drug substance, or they may be impermeable with one or more openings through which the drug substance may exit the device.
  • Such devices which are well-known in the art, provide additional control over the release rate of the drug substance, by controlling the diffusion rate and/or surface area through which the drug substance is released.
  • the drug substance in certain embodiments is a peptide or protein, which optionally may be pegylated, while in other embodiments the drug substance is a prodrug or a co-drug.
  • the drug substance may be in the form of a salt, which may be a low-solubility salt.
  • the drug substance is the diclofenate ester of morphine.
  • compositions of the invention may optionally contain additives, such as pore-forming agents (e.g., sugars, salts, and water-soluble polymers) and release rate modifiers (e.g., sterols, fatty acids, glycerol esters, and the like).
  • additives such as pore-forming agents (e.g., sugars, salts, and water-soluble polymers) and release rate modifiers (e.g., sterols, fatty acids, glycerol esters, and the like).
  • the invention provides a method for administering a drug substance to a subject, which comprises injecting into the subject a composition comprising (a) a drug substance; (b) a liquid PEG; and (c) a biocompatible and bioerodable PLGA polymer that is dissolved in the PEG.
  • a composition comprising (a) a drug substance; (b) a liquid PEG; and (c) a biocompatible and bioerodable PLGA polymer that is dissolved in the PEG.
  • subject refers to both human and animal patients to whom the drug is to be administered.
  • the invention provides a method for forming a polymeric sustained-release drug delivery gel in a subject, which comprises injecting into the subject a composition comprising (a) a drug substance; (b) a liquid PEG; and (c) a biocompatible and bioerodable PLGA polymer that is dissolved in the polyethylene glycol.
  • the present invention also provides for the co-administration of a PEG/polymer/drug fluid with an aqueous fluid, which may be for example normal saline or a hydrogel.
  • a PEG/polymer/drug fluid with an aqueous fluid, which may be for example normal saline or a hydrogel.
  • the two fluids are either administered at the same time via a double lumen needle, or mixed immediately before administration.
  • the two fluids may be in contained in attached syringes.
  • Co-administration reduces the local irritation that may be caused by direct application of highly concentrated PEGs.
  • the polymer may be any biocompatible PLGA polymer that is soluble in or miscible with PEG, and is less soluble in water. It is preferably water-insoluble, and is preferably a bioerodable polymer.
  • the carboxyl termini of the lactide- and glycolide-containing polymer may optionally be capped, e.g., by esterification, and the hydroxyl termini may optionally be capped, e.g., by etherification or esterification.
  • the polymer is PLGA having a lactide:glycolide molar ratio of between 20:80 and 90:10, more preferably between 50:50 and 85:15.
  • Bioerodable polymers are polymers which gradually degrade to smaller chemical fragments when placed in the subject's body. Two types of degradable polymers are included under this definition: biodegradable polymers (whose biodegradation is enzymatically mediated) and bioabsorbable polymers (which degrade to smaller fragments in the presence of water and/or other chemical species in the body). Some bioerodable polymers, e.g., certain block co-polymers, may be subject to both modes of degradation.
  • Biocompatible polymers are those polymers which, when injected or implanted in the subject's body, do not cause inflammation or irritation, do not induce an immune reaction, and do not exhibit toxicity.
  • the in situ gelling compositions of the present invention are suitable for delivering small organic molecules as well as peptides, proteins, polysaccharides, and nucleic acids.
  • the drug substance may be a pharmaceutically active substance, a pro-drug that is converted in vivo into a pharmaceutically active substance, or a co-drug that is converted in vivo into two or more pharmaceutically active substances.
  • co-drug is meant a combination of two or more drugs whose molecules are physically linked, for example by covalent or ionic bonds. Examples of suitable co-drugs are described in U.S. patent application Ser. No. 10/134,033 (publication US 2003/0039689) and U.S. patent application Ser. No. 10/349,202, which are incorporated herein by reference.
  • the drug substance may be soluble or insoluble in PEG. If insoluble, the drug substance is preferably suspended in the PEG in the form of fine particles.
  • drug substances suitable for use in the present invention include physiologically active peptides and/or proteins, antineoplastic agents, antibiotics, analgesics, anti-inflammatory agents, muscle relaxants, anti-epileptics, anti-ulcerative agents, anti-allergic agents, cardiotonics, anti-arrhythmic agents, vasodilators, antihypertensive agents, anti-diabetic agents, anti-hyperlipidemics, anticoagulants, hemolytic agents, antituberculous agents, hormones, narcotic antagonists, osteoclastic suppressants, osteogenic promoters, angiogenesis suppressors, and various mixtures, salts, prodrugs and co-drugs thereof.
  • Physiologically active peptides and/or proteins range in molecular weight from 200 to 100,000 and include but are not limited to human growth hormone, growth hormone releasing hormone, growth hormone releasing peptide, interferons, colony stimulating factors, interleukins, macrophage activating factors, macrophage peptide, B-cell factors, T-cell factors, protein A, allergy repressors, immunotoxins, lymphotoxins, tumor necrosis factors, tumor repression factors, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), metastasis growth factors, alpha-1 antitrypsin, apolipoprotein-E, erythropoietin, Factor VII, Factor VIII, Factor IX, plasminogen activating factors, urokinase, streptokinase, Protein C, C-reactive protein, superoxide dismutase, platelet-derived growth factors, epidermal growth factors, osteogenic growth factors, osteogenesis-promoting proteins, calc
  • Antiproliferative/antimitotic drugs and prodrugs include natural products such as vinca alkaloids (e.g., vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (e.g., etoposide, teniposide), antibiotics (e.g., actinomycins, daunorubicin, doxorubicin and idarubicin), anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin, enzymes (e.g., L-asparaginase); antiplatelet prodrugs; antiproliferative/antimitotic alkylating prodrugs such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa
  • the drug substance is a prodrug or co-drug of an opioid analgesic or an opioid antagonist.
  • opioids include morphine and morphine derivatives, such as apomorphine, buprenorphine, codeine, dihydrocodeine, dihydroetorphine, diprenorphine, etorphine, hydrocodone, hydromorphone, levorphanol, meperidine, metopon, o-methylnaltrexone, naloxone, naltrexone, normorphine, oxycodone, and oxymorphone.
  • morphine and morphine derivatives such as apomorphine, buprenorphine, codeine, dihydrocodeine, dihydroetorphine, diprenorphine, etorphine, hydrocodone, hydromorphone, levorphanol, meperidine, metopon, o-methylnaltrexone, naloxone, naltrexone, normorphine,
  • the opiod is fentanyl or a fentanyl derivative which can be derivatized to form a prodrug or co-drug, such as beta-hydroxy-3-methylfentanyl.
  • the drug substances may optionally be in pharmaceutically acceptable salt forms.
  • the polyethylene glycol solvent may be a PEG that is liquid at room temperature and ambient pressure, having an average MW of between about 100 and about 600, preferably between about 200 and about 400. Alternatively it may be a semi-solid or wax PEG, having an average molecular weight up to about 6,000.
  • the ratio of polyethylene glycol to polymer will typically range from about 25:1 to about 1:20 by weight.
  • compositions of the invention can be used to maintain therapeutically effective systemic levels of suitably potent drugs that have an appropriate elimination rate.
  • the invention can also be used to maintain therapeutically effective localized levels of suitably potent drugs having appropriate clearance rates.
  • compositions of the invention may be prepared by stirring PEG, the drug substance, and polymer together until solution is obtained. Dissolution may be accelerated by heating and agitation.
  • the drug substance is preferably provided in the form of a microparticulate or nanoparticulate powder that will form a suspension in the polymer-PEG solution.
  • the drug substance may be covalently linked to a polyoxyethylene ether (e.g., PEG), wherein the covalent bonds are cleavable in vivo so as to release the drug substance.
  • PEG polyoxyethylene ether
  • the drug substance is released in a sustained manner.
  • the drug substance is a pegylated prodrug of another drug substance.
  • the drug substance may be included in compounds having structure 1 below:
  • A is a residue of a pharmaceutically active agent A′
  • L represents a covalent bond or a linker moiety
  • S is a polyoxyethylene ether group having the formula —(OCH 2 CH 2 ) p OR, where p is 2-12 and R is a C 1 -C 4 alkyl group.
  • the biocompatible fluid may comprise a mixture of compounds having a range of values of p; but in preferred embodiments p has a single value and the composition comprises only one compound of structure 1.
  • the bond or linker L is cleavable in vivo so as to release the active agent A′.
  • the agent A′ will typically feature one or more functional groups to which linkers L can be readily attached. Examples of such functional groups include but are not limited to —CO 2 H, —CONH 2 , —CHO, ⁇ O, —OH, —NH 2 , and —SH groups.
  • bonds and linkages which are cleavable in vivo include but are not limited to esters, amides, carbamates, carbonates, orthoesters, cyclic ketals, thioesters, thioamides, thiocarbamates, thiocarbonates, xanthates, disulfides, and phosphate esters. Ester linkages, carbonate linkers, and/or amino acid linker moieties are preferred. Enzymatically cleavable linkers for polyoxyethylene derivatives have been described, for example, in U.S. Pat. No. 6,127,355, Ulbrich et al., Makromol. Chem.
  • m and n will typically range from 1 to 4, although larger values are within the scope of the invention.
  • the linker is divalent and m and n will have the same value, but multiple links to a single moiety S, as for example in a ketal or orthoester linkage, may be employed.
  • multiple moieties S may be appended via a single linker L, for example by esterification of the agent A with a moiety such as —C( ⁇ O)CH[OCH 2 CH 2 ) p OR] 2 or —P( ⁇ O)[(OCH 2 CH 2 ) p OR] 2 .
  • m>1 and/or n>1 each incidence of L and S may be the same or different.
  • the residue represented by A may be derived from any drug substance, including but not limited to steroids (preferably corticosteroids), retinoids, NSAIDs, vitamin D3 and vitamin D3 analogs, antibiotics, and antiviral agents.
  • steroids preferably corticosteroids
  • retinoids preferably retinoids
  • NSAIDs preferably corticosteroids
  • vitamin D3 and vitamin D3 analogs include antibiotics, and antiviral agents.
  • Other suitable agents include enzymes, peptides and other large molecules.
  • all-trans retinoic acid is excluded from the residues represented by A, while in other embodiments retinoids are excluded from the residues represented by A.
  • Suitable steroids include but are not limited to androgenic and estrogenic steroid hormones, androgen receptor antagonists and 5- ⁇ -reductase inhibitors, and corticosteroids. Specific examples include but are not limited to alclometasone, clobetasol, fluocinolone, fluocortolone, diflucortolone, fluticasone, halcinonide, mometasone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, and dexamethasone, and various esters and acetonides thereof.
  • Suitable retinoids include but are not limited to retinol, retinal, isotretinoin, acitretin, adapalene, tazarotene, and bexarotene.
  • Suitable NSAIDs include but are not limited to naproxen, suprofen, ketoprofen, ibuprofen, flurbiprofen, diclofenac, indomethacin, celecoxib, and rofecoxib.
  • Suitable vitamin D3 analogues include but are not limited to doxercalciferol, seocalcitol, calcipotriene, tacalcitol, calcitriol, ergocalciferol, and calcifediol.
  • Suitable antiviral agents include but are not limited to trifluridine, cidofovir, acyclovir, penciclovir, famciclovir, valcyclovir, gancyclovir, and docosanol.
  • Suitable antibacterial agents include but are not limited to metronidazole, clindamycin, erythromycin, vancomycin, ciprofloxacin, ofloxacin, lomefloxacin, bacitracin, neomycin, mupirocin, and polymyxin B.
  • the antiviral and antibacterial prodrugs of the invention may be used to treat appropriately responsive systemic infections.
  • the linker L is cleavable in vivo, meaning that the compound of the invention is hydrolyzed or otherwise cleaved, with or without enzymatic catalysis, so as to generate in situ the active drug substance.
  • Suitable linkers include, but are not limited to, —CH 2 O—, —OCH 2 O—, —C( ⁇ O)—O—, —OC( ⁇ O)—O—, —C( ⁇ O)—(CH 2 ) 1-4 —O—, and —C( ⁇ O)—(CH 2 ) 1-4 —, —C( ⁇ O)—NH—, and —C( ⁇ S)—NH—.
  • the linker or bond L may be attached to any suitable heteroatom present in the topically active agent that carries an exchangeable hydrogen, such as —OH, SH, NH 2 , and COOH groups.
  • an exchangeable hydrogen such as —OH, SH, NH 2 , and COOH groups.
  • the free hydroxyl group of triamcinolone acetonide may be acylated with the moiety —C( ⁇ O)(OCH 2 CH 2 ) p OR.
  • the active drug substance comprises a carboxylic acid group
  • the carboxylic acid group is esterified with a polyoxyethylene ether of formula HO(CH 2 CH 2 O) p R.
  • Examples include but are not limited to structures I, II, and III shown below:
  • the active drug substance comprises a hydroxyl group
  • the hydroxyl group is acylated with a polyoxyethylene ether carbonyl moiety of formula —CO(OCH 2 CH 2 ) p OR.
  • Examples include but are not limited to structures IV and V shown below:
  • n is an integer from 2 to 6 inclusive.
  • the identities of the group R may be methyl, ethyl, or any other organic moiety.
  • the use of prodrug linkages in connection with a drug substance may improve the solubility of an agent in water or in polymer.
  • the use of a pegylated prodrug may improve the solubility of an agent in the biocompatible fluid, and thereby improve the injectability of the invention.
  • the use of prodrug linkages may also lower the melting point of a solid drug substance, or increase the solubility of a drug substance in physiological fluids, thereby improving the injectability of the drug substance.
  • the drug substance may be dissolved, dispersed or suspended in the biocompatible core, whereupon it may leach out of the core and into surrounding fluid.
  • the drug substance may rapidly escape from an injection mixture after injection into a physiological system.
  • residue when applied to an agent means a part of an agent that is substantially identical to the agent from which it is derived, with minor differences arising by virtue of having one or more atoms removed to provide points of attachment for the linker(s) L.
  • at least one functional group of the residue will be altered (relative to the parent pharmaceutically active agent) to accommodate the covalent linker. This will typically involve removal of an exchangeable hydrogen and/or a single heteroatom, leaving a free valence for attachment of the linkage L.
  • the residue of the agent formed by removal of a hydroxyl group may form an ester bond with a hydroxyl group on a polyoxyethylene ether residue, which itself is formed by removal of a hydrogen atom from a hydroxyl group from the polyoxyethylene ether.
  • the term “residue” as used herein is analogous to the sense of the word as it is used in peptide and protein chemistry to refer to a residue of an amino acid in a peptide.
  • linker refers to a direct bond or to a multivalent group of atoms incorporating and connecting the functional groups of the active drug substance and a polyoxyethylene ether, which is metabolized under physiological conditions to release the active agent A′.
  • the linker is a substantially linear moiety having no more than 25 atoms, more preferably less than 10 atoms.
  • Preferred linkers are ones which, upon release of the topically active agent, and when further metabolized, generate byproducts that are non-toxic and inert at the effective dosing concentration. Direct bonds between the residue A and the polyoxyethylene moiety S are particularly preferred.
  • Formulation A was formulated at about 10 mg/ml morphine-diclofenac co-drug in PLGA (70:30)/PEG 400 solution ( ⁇ 5% (w/v) PLGA in PEG).
  • Formulation B was formulated at about 10 mg/ml morphine-diclofenac co-drug in PLGA (70:30)/PEG 400 solution ( ⁇ 10% (w/v) PLGA in PEG).
  • Formulation C was formulated at about 10 mg/ml morphine-diclofenac co-drug in PLGA (70:30)/PEG 400 solution ( ⁇ 20% (w/v) PLGA in PEG).
  • Each formulation was loaded into a 1-ml syringe, and 100 ⁇ l aliquot was injected into a tube containing 10 ml of 10% plasma in HA (hyaluronic acid) phosphate buffer, pH 7.4. The samples were placed in a water bath at 37° C. for release study. At each time point, the entire release medium was removed and replaced with 10 ml fresh buffer. The removed solution was analyzed for morphine, diclofenac and the co-drug contents by HPLC.
  • HA hyaluronic acid
  • the formulation was prepared with 12 mg/ml morphine-diclofenac co-drug in PLGA (50:50)/PEG 400 solution ( ⁇ 5% (w/v) PLGA in PEG) and loaded into a 1-ml syringe, and 100 ⁇ l aliquot was injected into a test tube containing 10 ml of 10% plasma in HA (hyaluronic acid) phosphate buffer, pH 7.4. The samples were placed in a 37° C. water bath. At each time point, the entire release medium was removed and replaced with 10 ml fresh buffer. The removed solutions were analyzed for morphine, diclofenac and the co-drug contents by HPLC.
  • Formulation A was formulated at about 8 mg/ml morphine-diclofenac co-drug in PLGA (70:30)/DMA solution (40% (w/v) PLGA in DMA).
  • Formulation B was formulated at about 10 mg/ml morphine-diclofenac co-drug in PLGA (70:30)/benzyl benzoate solution (20% (w/v) PLGA in benzyl benzoate).
  • Each formulation was loaded into a 1-ml syringe, and 100 ⁇ l aliquot was injected into a tube containing 10 ml of 10% plasma in HA (hyaluronic acid) phosphate buffer, pH 7.4.
  • the samples were placed in a water bath at 37° C. for release study.
  • the entire release medium for the DMA formulation was removed and replaced with 10 ml fresh buffer, while only 5 ml release medium for the benzyl benzoate formulation was removed and replaced with 5 ml fresh buffer.
  • the removed solutions were analyzed for morphine, diclofenac and the co-drug contents by HPLC.
  • the results are shown in FIGS. 3 (DMA) and 4 (benzyl benzoate).
  • the morphine release profile from the DMA formulation is very similar to that from the formulation with 5% (w/v) PLGA in Example 2, although the concentration of PLGA in the DMA formulation was 40% (w/v). However, morphine release was slower in the benzyl benzoate formulation. At day 35 about 46% morphine was released.
  • DMA is more hydrophilic than benzyl benzoate, which is an oily solvent. By adding these organic solvent(s) to PLGA formulations, drug release rate can be adjusted.

Abstract

The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 10/877,758, filed Jun. 25, 2004, which claims the benefit of U.S. Provisional Application No. 60/482,677, filed Jun. 26, 2003, and U.S. Provisional Application No. 60/575,307, filed May 28, 2004, the specifications of which are incorporated by reference herein in their entirety.
    • FIELD OF THE INVENTION
  • The present invention relates to the field of controlled-release and sustained-release drug delivery systems, and particularly to the field of injectable drug delivery implants.
    • BACKGROUND OF THE INVENTION
  • There are many useful drugs on the market today for which traditional means of administration are far from ideal. Bolus injections and oral unit doses typically result in a high initial systemic concentration of the active agent, in excess of the therapeutic concentration, which falls off over time and which will fall below the therapeutic concentration if another bolus is not timely administered. The result is that the ideal therapeutic concentration is not consistently maintained, there is a risk of toxicity associated with high systemic exposure to the drug, and the maintenance of a minimally effective concentration is dependent upon repeated administration at prescribed intervals. Patient compliance with a dosing regimen is difficult to ensure, especially where the course of therapy is long or of indeterminate or lifetime duration. There is a need for methods to deliver these drugs more effectively, so that therapeutic concentrations are maintained constantly in the tissues intended to be treated over an extended period of time, with minimal vulnerability to the vagaries of patient compliance, and ideally with minimal systemic exposure or exposure of uninvolved tissues and organs.
  • Modern drug discovery methods have led to the development of many drugs which are far more potent, yet have poorer solubility, than drugs developed through traditional medicinal chemistry methods. The development of these often-complex drugs has resulted in a need for methods to deliver such drugs more effectively and efficiently as well.
  • Extended-release and controlled-release drug delivery systems have been developed to address these needs. Implanted pumps and reservoirs, with various mechanisms for regulating release of drugs, were among the first solutions to be developed. A wide variety of polymeric matrices, permeated with drug substance, have also been developed which serve as implantable drug reservoirs. These polymeric implants gradually release drug over the course of days, weeks, or months as the contained drug diffuses through and out of the matrix and into the surrounding tissue. Three principal advantages provided by polymeric drug delivery compositions are:
  • (1) Localized delivery of drug. The product can be implanted directly at the site where drug action is needed and hence systemic exposure of the drug can be reduced. This becomes especially important for toxic drugs which are related to various systemic side effects (such as the chemotherapeutic drugs).
  • (2) Sustained delivery of drug. The drug is released over extended periods, eliminating the need for multiple injections or oral doses. This improves patient compliance, especially for drugs for chronic indications requiring frequent administration, such as replacement therapy for enzyme or hormone deficiencies, or for extended antibiotic treatments for such tenacious diseases as tuberculosis.
  • (3) Stabilization of the drug. The polymer matrix protects the drug from the physiological environment, particularly circulating enzymes, thereby improving stability in vivo. This makes the technology particularly attractive for the delivery of labile proteins and peptides.
  • For the reasons above, the use of drug-infused polymer implants as sustained-release drug delivery devices is now well established. One class of existing implants consists of preformed devices, ranging in size from matchstick-sized cylindrical rods such as the Norplant™ (levonorgestrel) and Zoladex™ (goserelin acetate) implants, to microspheres such as are sold under the trade name Lupron Depot™ (leuprolide acetate).
  • A major disadvantage of the macroscopic devices is their physical size. Implantation of Zoladex™ rods, for instance, requires the use of 14- or 16-gauge needles, and implantation of Norplant™ rods requires a surgical incision under local anesthesia, with similar subsequent procedures to replace and/or remove them. (The Zoladex™ rods are bioerodable, whereas Norplant™ implants are based on a non-bioerodable silicone.) Self-administration of such implants is not feasible, and the required intervention of trained medical personnel greatly raises the cost and inconvenience of such treatments.
  • Drug-containing polymer implants have been reduced in size by the expedient of grinding or milling a mixture of a drug substance and a gel-forming polymer at low temperature, as described in U.S. Pat. No. 5,385,738. The resulting powder is then suspended in a non-aqueous viscous solvent, such polyethylene glycol or a biocompatible oil, to obtain an injectable composition.
  • The size problem has similarly been overcome with microsphere implants, which can be administered (and self-administered where appropriate) by injection of an aqueous suspension of the microspheres. Lupron Depot™, for example, can be comfortably injected with a 22- or 23-gauge needle. Because microspheres are not retrievable from the body, they are necessarily based on bioerodable polymers. However, if an aqueous suspension of microspheres is stored for any length of time, the drug will diffuse from the particles into the aqueous phase, furthermore the bioerodable matrix itself is prone to hydrolysis in an aqueous environment. For these reasons, the injectable aqueous suspension must be prepared at the time of injection. A second disadvantage is the need for intramuscular injection. Finally, preparation of the microspheres is a complex process that is not easily carried out reproducibly and reliably, and regulatory validation of the manufacturing process can be a significant obstacle to commercialization of such products.
  • Another class of implants differing from pre-formed solid devices is injectable liquids. Upon injection, these are transformed in situ into solid implants. This class of implants is typified by compositions that transform from a drug-containing liquid phase to a drug-infused gel phase upon exposure to a physiological environment. Such in situ gelling compositions have several advantages: they can be readily and reliably manufactured by standard methods, they can be stored in the form of easily-injected liquids, they can be placed locally to achieve local delivery, and they can flow prior to gelling so as to fill voids and create a less-visible subcutaneous implant. In addition, a gelling implant can serve as a scaffold for cellular colonization and tissue growth.
  • There are various changes in conditions that can trigger the gelling of an in situ gelling composition. Among these are changes in pH, osmolality, temperature, water concentration, and alterations in specific ion concentrations.
  • Temperature-sensitive in situ gelling compositions generally change from a sol to a gel when the temperature exceeds a critical solution temperature, which in the case of drug delivery systems must be reasonably close to body temperature. An example is the polyethylene oxide-polypropylene oxide block copolymer, sold under the trade name Pluronic™ F 127. A 25-40% aqueous solution of this material will gel at about body temperature, and drug release from such a gel occurs over a period of up to one week. Such compositions have the disadvantage that they must be carefully protected from premature gelling, through refrigerated storage, and no bioerodable polymer has yet been developed that undergoes a sol-gel transition at about body temperature.
  • A hydrogel whose drug release profile is both temperature- and pH-modulated has also been reported (T. G. Park, in Biomaterials 20:517-521 (1999)).
  • Another class of compositions form gels upon contact with water. For example, glycerol monooleate (GMO) containing a drug can be injected as a liquid lamellar phase, which upon injection and exposure to water forms a highly viscous cubic-phase hydrate. The drug is released from the cubic phase over the course of several days. An example of an injectable drug depot product based on GMO is the metronidazole dental gel formulation marketed under the trade name Elyzol™. Due to the high water content of the cubic phase, GMO formulations are prone to rapid drug release and are limited in duration of effect to no more than about five days.
  • There are very few biocompatible liquid crystal compositions that meet the requirement for phase transition to a sufficiently viscous state at physiological conditions. Polymers that precipitate upon contact with water, on the other hand, are numerous, and present a more versatile approach to the formulation of compositions that gel upon contact with water. Approaches based on in situ gelling compositions are described in U.S. Pat. Nos. 4,938,763, 5,077,049, 5,278,202, 5,324,519 and 5,780,044, all of which are incorporated herein by reference.
  • For example, the Atrigel™ drug delivery system consists of a bioerodable poly(DL-lactide-glycolide) (PLGA) copolymer (75:25 molar ratio) dissolved in N-methyl-2-pyrrolidone (NMP). Pharmaceuticals may be blended into this PLGA solution at the point of manufacture, or they may be added by the physician at the time of use. The liquid product is injected subcutaneously or intramuscularly through a small gauge needle, whereupon displacement of the NMP carrier with water in the tissue fluids causes the PLGA to precipitate, forming a solid film or implant. The drug incorporated within the implant is then released in a controlled manner as the polymer matrix erodes with time in the body. PLGA-based implants of this type can release drug over a period of several months. An example of a product employing this technology is the leuprolide acetate formulation marketed under the trade name Eligard™.
  • The Atrigel™ system uses N-methylpyrrolidinone (NMP) as a solvent for the PLGA copolymer. NMP is a water-miscible, low-molecular-weight and low-viscosity solvent that rapidly diffuses from the implant. Rapid solvent escape from the injected composition can lead to rapid and uneven precipitation of the polymer, shrinking of the implant, and local irritation or even necrosis due to exposure of tissues to a high local concentration of solvent.
  • The use of liquid polymers as solvents for in situ gel-forming compositions has been described in U.S. Pat. No. 5,607,686 and in U.S. application Ser. No. 10/169,012 (US 2003/0082234), corresponding to international patent application PCT/KR00/01508 (WO 01/45742). However, according to these patents, polyethylene glycol is not suitable as a solvent for PLGA.
  • In situ polymer-precipitation systems solve many of the problems associated with implants, but some difficulties remain. There is a need for in situ gelling drug delivery systems with improved properties, a simple preparation procedure and low toxicity of excipient.
  • PEGs have the advantage of solubilizing different drugs than NMP; in particular pegylated proteins can be expected to be more soluble and/or miscible in PEGs than in NMP. An additional advantage is that PEGs are available in different molecular weights and have different viscosities. In many instances it important to be able to control the viscosity of the injected gelling agent, which is not possible with NMP.
    • BRIEF DESCRIPTION OF THE INVENTION
  • The morphology of the polymer gel produced during the precipitation process is dependent upon the nature of the organic solvent, which can vary from a dense sponge-like structure to an open meshwork with numerous voids and channels (P. D. Graham et al., J. Controlled Release 58:233-245 (1999)). This morphology in turn affects both the initial burst and the sustained release kinetics of the gel. Solvents used to date for this purpose have largely been selected from the chemist's traditional menu of low-molecular weight species, such as NMP, DMA, alcohols, and the like, as described for example in U.S. Pat. No. 5,780,044.
  • Applicants have found that polyethylene glycol can serve as the solvent for PLGA, and have found that the gel phase produced upon exchange of the PEG with water exhibits desirable sustained-release kinetics for small-molecule drugs.
  • Accordingly, the present invention provides an in situ gelling drug delivery formulation comprising a drug substance and a PLGA polymer, dissolved dispersed or suspended in PEG as the liquid phase solvent. In certain embodiments, the liquid phase solvent may include, or even consist essentially of, a prodrug of the drug substance combined with PEG. The compositions of the invention, on contact with water or bodily fluids, undergo exchange of the PEG for water, resulting in precipitation of the both the polymer and the drug and subsequent formation of a gel phase within which the drug substance is incorporated. The drug substance subsequently diffuses from the gel over an extended period of time.
  • The present invention also provides methods for making in situ gelling drug delivery formulations comprising a drug substance and a PLGA polymer, dissolved dispersed or suspended in PEG as the liquid phase solvent. The invention also provides methods for preparing sustained-release drug depots in situ by the use of such formulations.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the release profiles for morphine from three different morphine-diclofenac co-drug/PLGA (70:30)/PEG 400 formulations.
  • FIG. 2 shows the release profile for morphine from a morphine-diclofenac co-drug/PLGA (50:50)/PEG 400 formulation (5% w/v PLGA in PEG).
  • FIG. 3 shows the release profile for morphine from a morphine-diclofenac co-drug/PLGA (70:30)/DMA formulation.
  • FIG. 4 shows the release profile for morphine from a morphine-diclofenac co-drug/PLGA (70:30)/benzyl benzoate formulation (20% w/v PLGA in benzyl benzoate).
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides injectable in situ gelling pharmaceutical compositions, comprising: (a) a drug substance; (b) a liquid, semi-solid, or wax polyethylene glycol (PEG); and (c) a biocompatible and bioerodable polymer that is dissolved, dispersed, or suspended in the PEG.
  • A “liquid” PEG is a polyethylene glycol that is a liquid at 20-30° C. and ambient pressure. In certain preferred embodiments, the average MW of the liquid PEG is between about 200 and about 400. The polyethylene glycol may be linear or it may be a bioabsorbable branched PEG, for example as disclosed in U.S. Patent application No. 2002/0032298. In certain alternative embodiments the PEG may be a semi-solid or wax, in which case the Mn will be larger, for example 3,000 to 6,000. It will be understood that compositions comprising semi-solid and waxy PEGs may not be amenable to injection, and will accordingly be implanted by alternative means.
  • In certain embodiments, the drug substance is dissolved in the polyethylene glycol, while in other embodiments the drug substance is dispersed or suspended in the PEG in the form of solid particles. In yet other embodiments, the drug substance may be encapsulated or otherwise incorporated into particles, such as microspheres, nanospheres, liposomes, lipospheres, micelles, and the like, or it may be conjugated to a polymeric carrier. Any such particles are preferably less than about 500 microns in diameter, more preferably less than about 150 microns.
  • The present invention also provides for macroscopic drug delivery devices, for example in the form of hollow particles, capsules or open tubes, which contain an in situ gelling composition of the invention. The devices may be permeable to the drug substance, or they may be impermeable with one or more openings through which the drug substance may exit the device. Such devices, which are well-known in the art, provide additional control over the release rate of the drug substance, by controlling the diffusion rate and/or surface area through which the drug substance is released.
  • The drug substance in certain embodiments is a peptide or protein, which optionally may be pegylated, while in other embodiments the drug substance is a prodrug or a co-drug. The drug substance may be in the form of a salt, which may be a low-solubility salt. In certain embodiments exemplified herein, the drug substance is the diclofenate ester of morphine.
  • The compositions of the invention may optionally contain additives, such as pore-forming agents (e.g., sugars, salts, and water-soluble polymers) and release rate modifiers (e.g., sterols, fatty acids, glycerol esters, and the like).
  • In another aspect, the invention provides a method for administering a drug substance to a subject, which comprises injecting into the subject a composition comprising (a) a drug substance; (b) a liquid PEG; and (c) a biocompatible and bioerodable PLGA polymer that is dissolved in the PEG. As used herein, “subject” refers to both human and animal patients to whom the drug is to be administered.
  • In yet another aspect, the invention provides a method for forming a polymeric sustained-release drug delivery gel in a subject, which comprises injecting into the subject a composition comprising (a) a drug substance; (b) a liquid PEG; and (c) a biocompatible and bioerodable PLGA polymer that is dissolved in the polyethylene glycol.
  • The present invention also provides for the co-administration of a PEG/polymer/drug fluid with an aqueous fluid, which may be for example normal saline or a hydrogel. In this embodiment, the two fluids are either administered at the same time via a double lumen needle, or mixed immediately before administration. The two fluids may be in contained in attached syringes. Co-administration reduces the local irritation that may be caused by direct application of highly concentrated PEGs.
  • The polymer may be any biocompatible PLGA polymer that is soluble in or miscible with PEG, and is less soluble in water. It is preferably water-insoluble, and is preferably a bioerodable polymer. The carboxyl termini of the lactide- and glycolide-containing polymer may optionally be capped, e.g., by esterification, and the hydroxyl termini may optionally be capped, e.g., by etherification or esterification. Preferably the polymer is PLGA having a lactide:glycolide molar ratio of between 20:80 and 90:10, more preferably between 50:50 and 85:15.
  • Bioerodable polymers are polymers which gradually degrade to smaller chemical fragments when placed in the subject's body. Two types of degradable polymers are included under this definition: biodegradable polymers (whose biodegradation is enzymatically mediated) and bioabsorbable polymers (which degrade to smaller fragments in the presence of water and/or other chemical species in the body). Some bioerodable polymers, e.g., certain block co-polymers, may be subject to both modes of degradation.
  • Biocompatible polymers are those polymers which, when injected or implanted in the subject's body, do not cause inflammation or irritation, do not induce an immune reaction, and do not exhibit toxicity.
  • The in situ gelling compositions of the present invention are suitable for delivering small organic molecules as well as peptides, proteins, polysaccharides, and nucleic acids. The drug substance may be a pharmaceutically active substance, a pro-drug that is converted in vivo into a pharmaceutically active substance, or a co-drug that is converted in vivo into two or more pharmaceutically active substances. By co-drug is meant a combination of two or more drugs whose molecules are physically linked, for example by covalent or ionic bonds. Examples of suitable co-drugs are described in U.S. patent application Ser. No. 10/134,033 (publication US 2003/0039689) and U.S. patent application Ser. No. 10/349,202, which are incorporated herein by reference. The drug substance may be soluble or insoluble in PEG. If insoluble, the drug substance is preferably suspended in the PEG in the form of fine particles.
  • By way of example, and not limitation, drug substances suitable for use in the present invention include physiologically active peptides and/or proteins, antineoplastic agents, antibiotics, analgesics, anti-inflammatory agents, muscle relaxants, anti-epileptics, anti-ulcerative agents, anti-allergic agents, cardiotonics, anti-arrhythmic agents, vasodilators, antihypertensive agents, anti-diabetic agents, anti-hyperlipidemics, anticoagulants, hemolytic agents, antituberculous agents, hormones, narcotic antagonists, osteoclastic suppressants, osteogenic promoters, angiogenesis suppressors, and various mixtures, salts, prodrugs and co-drugs thereof.
  • Physiologically active peptides and/or proteins range in molecular weight from 200 to 100,000 and include but are not limited to human growth hormone, growth hormone releasing hormone, growth hormone releasing peptide, interferons, colony stimulating factors, interleukins, macrophage activating factors, macrophage peptide, B-cell factors, T-cell factors, protein A, allergy repressors, immunotoxins, lymphotoxins, tumor necrosis factors, tumor repression factors, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), metastasis growth factors, alpha-1 antitrypsin, apolipoprotein-E, erythropoietin, Factor VII, Factor VIII, Factor IX, plasminogen activating factors, urokinase, streptokinase, Protein C, C-reactive protein, superoxide dismutase, platelet-derived growth factors, epidermal growth factors, osteogenic growth factors, osteogenesis-promoting proteins, calcitonin, insulin, atriopeptin, cartilage induction factors, connective tissue activating factors, follicle stimulating hormone, leutenizing hormone, leutenizing hormone releasing hormone, nerve growth factors, parathyroid hormone, relaxin, secretin, somatomedin, insulin-like growth factors, adrenocorticotropic hormone, glucagons, cholecystokinin, pancreatic polypeptides, gastrin releasing hormone, coticotropin releasing factors, thyroid stimulating hormones, mono- and poly-clonal antibodies, vaccines, and mixtures thereof. Pegylated versions of proteins, peptides, or other biologic response modifiers are also suitable for incorporation into the compositions of the present invention.
  • Antiproliferative/antimitotic drugs and prodrugs include natural products such as vinca alkaloids (e.g., vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (e.g., etoposide, teniposide), antibiotics (e.g., actinomycins, daunorubicin, doxorubicin and idarubicin), anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin, enzymes (e.g., L-asparaginase); antiplatelet prodrugs; antiproliferative/antimitotic alkylating prodrugs such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nitrosoureas (carmustine (BCNU) and analogs, streptozocin), triazenes, dacarbazine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate), pyrimidine analogs (fluorouracil, floxuridine, and cytarabine), purine analogs and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine (cladribine); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones (e.g., estrogen, progestin); anticoagulants (e.g., heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic prodrugs such as tissue plasminogen activator, streptokinase and urokinase, aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory; antisecretory (breveldin); anti-inflammatory agents such as corticosteroids (cortisol, cortisone, fludrocortisone, flucinolone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, and dexamethasone), NSAIDS (salicylic acid and derivatives, aspirin, acetaminophen, indole and indene acetic acids (indomethacin, sulindac and etodalac), heteroaryl acetic acids (tolmetin, diclofenac, and ketorolac), arylpropionic acids (e.g., ibuprofen and derivatives), anthranilic acids (mefenamic acid, and meclofenamic acid), enolic acids (piroxicam, tenoxicam, phenylbutazone, and oxyphenthatrazone), nabumetone, gold compounds (auranofin, aurothioglucose, gold sodium thiomalate); immunosuppressives (e.g., cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, and mycophenolate mofetil); angiogenic agents such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF); angiotensin receptor blocker; nitric oxide donors; anti-sense oligionucleotides and combinations thereof; cell cycle inhibitors, mTOR inhibitors, and growth factor signal transduction kinase inhibitors.
  • In certain embodiments, the drug substance is a prodrug or co-drug of an opioid analgesic or an opioid antagonist. Exemplary opioids include morphine and morphine derivatives, such as apomorphine, buprenorphine, codeine, dihydrocodeine, dihydroetorphine, diprenorphine, etorphine, hydrocodone, hydromorphone, levorphanol, meperidine, metopon, o-methylnaltrexone, naloxone, naltrexone, normorphine, oxycodone, and oxymorphone. In other embodiments, the opiod is fentanyl or a fentanyl derivative which can be derivatized to form a prodrug or co-drug, such as beta-hydroxy-3-methylfentanyl. The drug substances may optionally be in pharmaceutically acceptable salt forms.
  • The polyethylene glycol solvent may be a PEG that is liquid at room temperature and ambient pressure, having an average MW of between about 100 and about 600, preferably between about 200 and about 400. Alternatively it may be a semi-solid or wax PEG, having an average molecular weight up to about 6,000. The ratio of polyethylene glycol to polymer will typically range from about 25:1 to about 1:20 by weight.
  • The compositions of the invention can be used to maintain therapeutically effective systemic levels of suitably potent drugs that have an appropriate elimination rate. The invention can also be used to maintain therapeutically effective localized levels of suitably potent drugs having appropriate clearance rates.
  • The compositions of the invention may be prepared by stirring PEG, the drug substance, and polymer together until solution is obtained. Dissolution may be accelerated by heating and agitation. Where the drug substance is not soluble in the PEG, the drug substance is preferably provided in the form of a microparticulate or nanoparticulate powder that will form a suspension in the polymer-PEG solution.
  • In certain embodiments, the drug substance may be covalently linked to a polyoxyethylene ether (e.g., PEG), wherein the covalent bonds are cleavable in vivo so as to release the drug substance. In certain embodiments, the drug substance is released in a sustained manner. Methods shown for forming and applying conjugate prodrugs (e.g., PEG—drug conjugates) are shown in U.S. Pat. No. 5,681,964 and in U.S. Provisional Application No. 60/539,306, the specifications of which are incorporated by reference in their entirety herein.
  • In certain embodiments, the drug substance is a pegylated prodrug of another drug substance.
  • In certain embodiments the drug substance may be included in compounds having structure 1 below:

  • A(-L-)mSn  1
  • wherein A is a residue of a pharmaceutically active agent A′, L represents a covalent bond or a linker moiety, and S is a polyoxyethylene ether group having the formula —(OCH2CH2)pOR, where p is 2-12 and R is a C1-C4 alkyl group. The biocompatible fluid may comprise a mixture of compounds having a range of values of p; but in preferred embodiments p has a single value and the composition comprises only one compound of structure 1. The bond or linker L is cleavable in vivo so as to release the active agent A′. The agent A′ will typically feature one or more functional groups to which linkers L can be readily attached. Examples of such functional groups include but are not limited to —CO2H, —CONH2, —CHO, ═O, —OH, —NH2, and —SH groups.
  • Examples of bonds and linkages which are cleavable in vivo, either by hydrolysis or by enzyme catalysis, include but are not limited to esters, amides, carbamates, carbonates, orthoesters, cyclic ketals, thioesters, thioamides, thiocarbamates, thiocarbonates, xanthates, disulfides, and phosphate esters. Ester linkages, carbonate linkers, and/or amino acid linker moieties are preferred. Enzymatically cleavable linkers for polyoxyethylene derivatives have been described, for example, in U.S. Pat. No. 6,127,355, Ulbrich et al., Makromol. Chem. 1986; 187:1131-1144, Conover et al., and Anti-Cancer Drug Design 1999; 14:499-506, and in many of the references cited therein, and the use of such linkers is specifically contemplated. Ester linkages may also be used (see R. Bronaugh et al., Percutaneous Absorption 3rd Ed., p. 58-63, R. L. Bronaugh and H. I. Maibach, eds., Marcel Dekker, New York, 1999).
  • The values of m and n will typically range from 1 to 4, although larger values are within the scope of the invention. Typically, the linker is divalent and m and n will have the same value, but multiple links to a single moiety S, as for example in a ketal or orthoester linkage, may be employed. Alternatively, multiple moieties S may be appended via a single linker L, for example by esterification of the agent A with a moiety such as —C(═O)CH[OCH2CH2)pOR]2 or —P(═O)[(OCH2CH2)pOR]2. Where m>1 and/or n>1, each incidence of L and S may be the same or different.
  • The residue represented by A may be derived from any drug substance, including but not limited to steroids (preferably corticosteroids), retinoids, NSAIDs, vitamin D3 and vitamin D3 analogs, antibiotics, and antiviral agents. Other suitable agents include enzymes, peptides and other large molecules. In certain embodiments of this invention, all-trans retinoic acid is excluded from the residues represented by A, while in other embodiments retinoids are excluded from the residues represented by A.
  • Suitable steroids include but are not limited to androgenic and estrogenic steroid hormones, androgen receptor antagonists and 5-α-reductase inhibitors, and corticosteroids. Specific examples include but are not limited to alclometasone, clobetasol, fluocinolone, fluocortolone, diflucortolone, fluticasone, halcinonide, mometasone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, and dexamethasone, and various esters and acetonides thereof.
  • Suitable retinoids include but are not limited to retinol, retinal, isotretinoin, acitretin, adapalene, tazarotene, and bexarotene.
  • Suitable NSAIDs include but are not limited to naproxen, suprofen, ketoprofen, ibuprofen, flurbiprofen, diclofenac, indomethacin, celecoxib, and rofecoxib.
  • Suitable vitamin D3 analogues include but are not limited to doxercalciferol, seocalcitol, calcipotriene, tacalcitol, calcitriol, ergocalciferol, and calcifediol.
  • Suitable antiviral agents include but are not limited to trifluridine, cidofovir, acyclovir, penciclovir, famciclovir, valcyclovir, gancyclovir, and docosanol. Suitable antibacterial agents include but are not limited to metronidazole, clindamycin, erythromycin, vancomycin, ciprofloxacin, ofloxacin, lomefloxacin, bacitracin, neomycin, mupirocin, and polymyxin B. The antiviral and antibacterial prodrugs of the invention may be used to treat appropriately responsive systemic infections.
  • The linker L is cleavable in vivo, meaning that the compound of the invention is hydrolyzed or otherwise cleaved, with or without enzymatic catalysis, so as to generate in situ the active drug substance.
  • Examples of suitable linkers include, but are not limited to, —CH2O—, —OCH2O—, —C(═O)—O—, —OC(═O)—O—, —C(═O)—(CH2)1-4—O—, and —C(═O)—(CH2)1-4—, —C(═O)—NH—, and —C(═S)—NH—. Descriptions of suitable linkers may be found in Prodrugs: Topical and Ocular Drug Delivery, 1992, K. B. Sloan (Ed.), Drugs and the Pharmaceutical Sciences, Vol 53 (Marcel Dekker). It will be appreciated that the rate of cleavage will vary depending on the precise structures of the active agent and the polyoxyethylene ether, and on the nature of the linker or bond L and the point(s) of attachment. The efficiency of prodrug cleavage of linkers for any specific embodiment can be readily determined by those of skill in the art; for a review of methods see A. Stichcomb, 2003, Pharm Res. 20:1113-1118.
  • The linker or bond L may be attached to any suitable heteroatom present in the topically active agent that carries an exchangeable hydrogen, such as —OH, SH, NH2, and COOH groups. By way of example, the free hydroxyl group of triamcinolone acetonide may be acylated with the moiety —C(═O)(OCH2CH2)pOR.
  • In one embodiment, the active drug substance comprises a carboxylic acid group, and the carboxylic acid group is esterified with a polyoxyethylene ether of formula HO(CH2CH2O)pR. Examples include but are not limited to structures I, II, and III shown below:
  • Figure US20110165242A1-20110707-C00001
  • In an alternative embodiment, the active drug substance comprises a hydroxyl group, and the hydroxyl group is acylated with a polyoxyethylene ether carbonyl moiety of formula —CO(OCH2CH2)pOR. Examples include but are not limited to structures IV and V shown below:
  • Figure US20110165242A1-20110707-C00002
  • In certain embodiments, the biocompatible fluid includes a prodrug comprising a pharmaceutical compound linked to a polyoxyethylene ether moiety of the formula: —(OCH2CH2)pOR, wherein p=2-12 and R is a C1-C4 alkyl group. In certain embodiments, n is an integer from 2 to 6 inclusive. The identities of the group R may be methyl, ethyl, or any other organic moiety.
  • In certain embodiments, the use of prodrug linkages in connection with a drug substance may improve the solubility of an agent in water or in polymer. For example, the use of a pegylated prodrug may improve the solubility of an agent in the biocompatible fluid, and thereby improve the injectability of the invention. The use of prodrug linkages may also lower the melting point of a solid drug substance, or increase the solubility of a drug substance in physiological fluids, thereby improving the injectability of the drug substance.
  • The drug substance may be dissolved, dispersed or suspended in the biocompatible core, whereupon it may leach out of the core and into surrounding fluid. In certain embodiments, the drug substance may rapidly escape from an injection mixture after injection into a physiological system.
  • The term “residue” when applied to an agent means a part of an agent that is substantially identical to the agent from which it is derived, with minor differences arising by virtue of having one or more atoms removed to provide points of attachment for the linker(s) L. Typically, at least one functional group of the residue will be altered (relative to the parent pharmaceutically active agent) to accommodate the covalent linker. This will typically involve removal of an exchangeable hydrogen and/or a single heteroatom, leaving a free valence for attachment of the linkage L. For instance, where the drug substance includes a carboxylate functional group, the residue of the agent formed by removal of a hydroxyl group may form an ester bond with a hydroxyl group on a polyoxyethylene ether residue, which itself is formed by removal of a hydrogen atom from a hydroxyl group from the polyoxyethylene ether. In this sense, the term “residue” as used herein is analogous to the sense of the word as it is used in peptide and protein chemistry to refer to a residue of an amino acid in a peptide.
  • The terms “linker” and “linkage,” which are used interchangeably herein, refer to a direct bond or to a multivalent group of atoms incorporating and connecting the functional groups of the active drug substance and a polyoxyethylene ether, which is metabolized under physiological conditions to release the active agent A′. In certain embodiments, the linker is a substantially linear moiety having no more than 25 atoms, more preferably less than 10 atoms. Preferred linkers are ones which, upon release of the topically active agent, and when further metabolized, generate byproducts that are non-toxic and inert at the effective dosing concentration. Direct bonds between the residue A and the polyoxyethylene moiety S are particularly preferred.
    • EXAMPLES Example 1 Evaluation of Solubility of PLGA in Organic Solvents
  • A sample of PLGA polymer was added to the indicated solvent and rotated overnight at room temperature, and the resulting mixture was examined for undissolved material. The results are shown in Table 1 below.
  • TABLE 1
    Solubility of PLGA polymers in selected organic solvents
    Polymer Solvent Visual Appearance
    PLGA (70:30), 0.2 g PEG 400, 1 ml Clear solution
    PLGA (70:30), 0.2 g PEG 300, 2 ml Clear solution
    PLGA (70:30), 0.2 g PEG 200, 2 ml Clear solution
    PLGA (70:30), 0.1 g DMA, 20 Drops Clear solution
    PLGA (85:15), 0.1 g PEG 400, 1 ml Partially soluble*
    PLGA (50:50), 0.1 g PEG 400, 1 ml Partially soluble*
    PLGA (85:15), 0.1 g DMA, 1 ml Clear solution
    PLGA (50:50), 0.1 g DMA, 1 ml Clear solution
    PLGA (90:10), 0.1 g PEG 400, 2 ml Partially soluble*
    PLGA (70:30), 0.1 g Cremophor EL, 2 ml Partially soluble
    PLGA (70:30), 0.1 g Cremophor EL-P, 2 ml Partially soluble
    PLGA (70:30), 0.1 g Benzyl alcohol, 0.5 ml Clear solution
    PLGA (70:30), 0.1 g Benzyl benzoate, 0.5 ml Miscible solution
    *PLGA (50:50), PLGA (85:15) and PLGA (90:10) were supplied in pellet form and were slow to dissolve in PEG solvent.
  • When the solutions were slowly injected into water containing 0.9% NaCl, the injected samples were observed to form gels. The rate of gelation depended on the identity of the solvent, the ratio of solvent to polymer, and the lactide/glycolate ratio of the polymer.
    • Example 2 Release Profiles for Morphine-Diclofenac Co-Drug from PLGA (70:30)/PEG Formulations
  • Three formulations were evaluated to compare release profiles for morphine-diclofenac co-drug from different concentrations of PLGA (70:30): Formulation A was formulated at about 10 mg/ml morphine-diclofenac co-drug in PLGA (70:30)/PEG 400 solution (−5% (w/v) PLGA in PEG). Formulation B was formulated at about 10 mg/ml morphine-diclofenac co-drug in PLGA (70:30)/PEG 400 solution (˜10% (w/v) PLGA in PEG). Formulation C was formulated at about 10 mg/ml morphine-diclofenac co-drug in PLGA (70:30)/PEG 400 solution (˜20% (w/v) PLGA in PEG).
  • Each formulation was loaded into a 1-ml syringe, and 100 μl aliquot was injected into a tube containing 10 ml of 10% plasma in HA (hyaluronic acid) phosphate buffer, pH 7.4. The samples were placed in a water bath at 37° C. for release study. At each time point, the entire release medium was removed and replaced with 10 ml fresh buffer. The removed solution was analyzed for morphine, diclofenac and the co-drug contents by HPLC.
  • The results are shown graphically in FIG. 1. Morphine released much faster from the formulation A with 5% (w/v) PLGA. At day 18 about 80% morphine released. The release profiles of formulations B and C were very similar. At day 24 about 80% of the morphine was released from both formulations. However, the higher concentration of PLGA at 20% (w/v) reduced initial burst significantly. No morphine-diclofenac co-drug was detected since the co-drug was hydrolyzed in the release medium. Diclofenac data (not shown) was not reliable, due to the high protein binding of diclofenac in the serum medium.
    • Example 3 Release Rate Profile for Morphine-Diclofenac Co-Drug from PLGA (50:50)/PEG Formulation
  • The formulation was prepared with 12 mg/ml morphine-diclofenac co-drug in PLGA (50:50)/PEG 400 solution (˜5% (w/v) PLGA in PEG) and loaded into a 1-ml syringe, and 100 μl aliquot was injected into a test tube containing 10 ml of 10% plasma in HA (hyaluronic acid) phosphate buffer, pH 7.4. The samples were placed in a 37° C. water bath. At each time point, the entire release medium was removed and replaced with 10 ml fresh buffer. The removed solutions were analyzed for morphine, diclofenac and the co-drug contents by HPLC.
  • The results are shown graphically in FIG. 2. As compared to the results from Example 2, morphine release was much slower in this PLGA (50:50) formulation, even where the PLGA concentration was low as ˜5% (w/v). About 80% of the morphine was released over 40 days. It is most likely that the higher molecular weight of PLGA (50:50) reduces the release rate of morphine.
    • Example 4 Release Profiles for Morphine-Diclofenac Co-Drug from PLGA(70:30) with Non-Polymeric Solvents Two formulations were evaluated for this study: Formulation A was formulated at about 8 mg/ml morphine-diclofenac co-drug in PLGA (70:30)/DMA solution (40% (w/v) PLGA in DMA). Formulation B was formulated at about 10 mg/ml morphine-diclofenac co-drug in PLGA (70:30)/benzyl benzoate solution (20% (w/v) PLGA in benzyl benzoate).
  • Each formulation was loaded into a 1-ml syringe, and 100 μl aliquot was injected into a tube containing 10 ml of 10% plasma in HA (hyaluronic acid) phosphate buffer, pH 7.4. The samples were placed in a water bath at 37° C. for release study. At each time point, the entire release medium for the DMA formulation was removed and replaced with 10 ml fresh buffer, while only 5 ml release medium for the benzyl benzoate formulation was removed and replaced with 5 ml fresh buffer. The removed solutions were analyzed for morphine, diclofenac and the co-drug contents by HPLC.
  • The results are shown in FIGS. 3 (DMA) and 4 (benzyl benzoate). The morphine release profile from the DMA formulation is very similar to that from the formulation with 5% (w/v) PLGA in Example 2, although the concentration of PLGA in the DMA formulation was 40% (w/v). However, morphine release was slower in the benzyl benzoate formulation. At day 35 about 46% morphine was released. DMA is more hydrophilic than benzyl benzoate, which is an oily solvent. By adding these organic solvent(s) to PLGA formulations, drug release rate can be adjusted.
  • All references, publications, and patents cited herein are hereby incorporated by reference in their entirety. From the foregoing description, it will be apparent to one of ordinary skill in the art that, without departing from the spirit and scope thereof, various changes and/or modifications of the invention may be made to adapt it to particular usages and conditions. Such changes and/or modifications are contemplated to be within the full range of equivalence of the following claims.

Claims (10)

1. A sustained release injectable pharmaceutical composition comprising:
(a) a prodrug, comprising a drug substance covalently linked to a polyoxyethylene ether; and
(b) a biocompatible and bioerodable poly(DL-lactide-glycolide) (PLGA) polymer;
(c) wherein the prodrug serves as a solvent for the PLGA polymer and the PLGA polymer is dissolved in the prodrug; and
(d) wherein the composition forms a gel phase when said composition comes into contact with water or bodily fluids.
2. A method for forming a polymeric sustained-release drug delivery gel in a subject, comprising injecting into the subject a composition according to any one of claim 1.
3. A method of administering a composition according to claim 1 wherein the composition is co-administered with an aqueous fluid.
4. The method according to claim 3 wherein the aqueous fluid is buffered saline.
5. A drug delivery device containing a composition according to claim 1.
6. A device according to claim 5 wherein the device has at least one opening.
7. A device according to claim 5 wherein the device is an open tube.
8. The composition of claim 1, wherein the polyoxyethylene ether is polyethylene glycol (PEG).
9. The composition of claim 8, wherein the average MW of the polyethylene glycol is between about 100 and about 6000.
10. The composition of claim 8, wherein the average MW of the polyethylene glycol is between about 200 and about 400.
US12/870,616 2003-06-26 2010-08-27 In situ gelling drug delivery system Abandoned US20110165242A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/870,616 US20110165242A1 (en) 2003-06-26 2010-08-27 In situ gelling drug delivery system
US13/612,076 US20130101656A1 (en) 2003-06-26 2012-09-12 In situ gelling drug delivery system
US14/444,338 US9566336B2 (en) 2003-06-26 2014-07-28 In situ gelling drug delivery system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48267703P 2003-06-26 2003-06-26
US57530704P 2004-05-28 2004-05-28
US10/877,758 US20050048123A1 (en) 2003-06-26 2004-06-25 In situ gelling drug delivery system
US12/870,616 US20110165242A1 (en) 2003-06-26 2010-08-27 In situ gelling drug delivery system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/877,758 Continuation US20050048123A1 (en) 2003-06-26 2004-06-25 In situ gelling drug delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/612,076 Continuation US20130101656A1 (en) 2003-06-26 2012-09-12 In situ gelling drug delivery system

Publications (1)

Publication Number Publication Date
US20110165242A1 true US20110165242A1 (en) 2011-07-07

Family

ID=33567657

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/877,758 Abandoned US20050048123A1 (en) 2003-06-26 2004-06-25 In situ gelling drug delivery system
US12/870,616 Abandoned US20110165242A1 (en) 2003-06-26 2010-08-27 In situ gelling drug delivery system
US13/612,076 Abandoned US20130101656A1 (en) 2003-06-26 2012-09-12 In situ gelling drug delivery system
US14/444,338 Active US9566336B2 (en) 2003-06-26 2014-07-28 In situ gelling drug delivery system

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/877,758 Abandoned US20050048123A1 (en) 2003-06-26 2004-06-25 In situ gelling drug delivery system

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/612,076 Abandoned US20130101656A1 (en) 2003-06-26 2012-09-12 In situ gelling drug delivery system
US14/444,338 Active US9566336B2 (en) 2003-06-26 2014-07-28 In situ gelling drug delivery system

Country Status (16)

Country Link
US (4) US20050048123A1 (en)
EP (2) EP2044959A1 (en)
JP (1) JP5229768B2 (en)
CN (2) CN101862455A (en)
AR (1) AR044926A1 (en)
AT (1) ATE410186T1 (en)
CA (1) CA2530136C (en)
CY (1) CY1108685T1 (en)
DE (1) DE602004016995D1 (en)
DK (1) DK1635875T3 (en)
ES (1) ES2315680T3 (en)
PL (1) PL1635875T3 (en)
PT (1) PT1635875E (en)
SI (1) SI1635875T1 (en)
TW (1) TWI377958B (en)
WO (1) WO2005002625A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018227187A1 (en) * 2017-06-09 2018-12-13 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
CA2498191C (en) * 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
AU2004274026A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
EP1853259A1 (en) 2005-02-09 2007-11-14 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
JP4827626B2 (en) * 2006-06-14 2011-11-30 キヤノン株式会社 CONTROLLED DEVICE, REMOTE CONTROL SYSTEM, REMOTE CONTROL SYSTEM CONTROL METHOD, PROGRAM
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
JP2010531807A (en) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド Slow-broadcast formulation of risperidone compound
WO2009120358A1 (en) * 2008-03-27 2009-10-01 Nektar Therapeutics Oligomer-nitrogenous base conjugates
EP2234619A4 (en) * 2008-04-18 2010-10-27 Medtronic Inc Methods and compositions for treating intervertebral disc herniations
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB201014591D0 (en) * 2010-09-02 2010-10-13 Univ Nottingham Compositions
EP2643009A4 (en) * 2010-11-24 2015-04-01 Durect Corp Biodegradable drug delivery composition
CN103717206A (en) * 2011-07-27 2014-04-09 波利皮得有限公司 Matrix compositions for controlled release of peptide and polypeptide molecules
AU2014216112B2 (en) * 2013-02-15 2019-02-21 Allergan, Inc. Sustained drug delivery implant
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
CN107278151A (en) 2014-12-15 2017-10-20 约翰霍普金斯大学 Sutent preparation and its application method in treatment glaucoma
AR106085A1 (en) 2015-09-21 2017-12-13 Teva Pharmaceuticals Int Gmbh OLANZAPINE FORMULATIONS OF SUSTAINED RELEASE
TWI641387B (en) * 2015-10-29 2018-11-21 逸達生物科技股份有限公司 Pharmaceutical composition with improved stability
CA3004886A1 (en) 2015-11-12 2017-05-18 Graybug Vision, Inc. Aggregating microparticles for medical therapy
CN110691605A (en) * 2017-03-14 2020-01-14 费城儿童医院 Cleavable esters for nanocarrier-based cancer therapy
US10646443B2 (en) 2017-03-20 2020-05-12 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
CA3056923A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
US11167034B2 (en) 2017-06-13 2021-11-09 The University Of British Columbia Polymeric paste compositions for drug delivery
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
UY38386A (en) * 2018-09-25 2020-04-30 Tolmar Int Ltd LIQUID POLYMER DELIVERY SYSTEM FOR PROLONGED ADMINISTRATION OF DRUGS
CN111374940A (en) * 2020-04-13 2020-07-07 宁波赛缪斯生物科技有限公司 Collagen injection capable of in-situ polymerization and use method thereof
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
AU2022308198A1 (en) 2021-07-06 2024-02-01 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5616560A (en) * 1991-12-17 1997-04-01 The Procter & Gamble Company Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5744153A (en) * 1994-04-08 1998-04-28 Atrix Laboratories, Inc. Liquid delivery compositions
US6156764A (en) * 1996-02-28 2000-12-05 Lts Lohmann Therapie-Systeme Gmbh Morphine and diamorphine salts of anionic non-narcotic analgesics of the substituted carboxylic acid type
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20030082234A1 (en) * 1999-12-22 2003-05-01 Min-Hyo Seo Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
JPS59110607A (en) 1982-12-17 1984-06-26 シ−トン・カンパニ− Soft continuous film for medical cosmetics
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
WO1989009066A1 (en) 1988-03-24 1989-10-05 Bukh Meditec A/S Controlled release composition
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5110596A (en) 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9409281D0 (en) 1994-05-10 1994-06-29 Svedman Paul Transdermal device
US5607686A (en) 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
ATE203157T1 (en) 1996-12-20 2001-08-15 Alza Corp INJECTABLE DEPOSIT GEL PREPARATION AND PRODUCTION METHOD
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6102887A (en) * 1998-08-11 2000-08-15 Biocardia, Inc. Catheter drug delivery system and method for use
ES2213404T3 (en) 1998-12-17 2004-08-16 Alza Corporation TRANSFORMATION OF GELATINE CAPSULES FILLED WITH LIQUID IN CONTROLLED RELEASE SYSTEMS BY MULTIPLE COATINGS.
AU779277B2 (en) 1999-06-04 2005-01-13 Alza Corporation Implantable gel compositions and method of manufacture
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP1299048A4 (en) * 2000-06-28 2005-09-28 Atul J Shukla Biodegradable vehicles and delivery systems of biologically active substances
CN1206001C (en) * 2000-06-28 2005-06-15 A·J·舒克拉 Biodegradable carrier and biodegradable transfer system
EP2316490A3 (en) * 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
KR100446101B1 (en) * 2000-12-07 2004-08-30 주식회사 삼양사 Sustained delivery composition for poorly water soluble drugs
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
EP1383504A1 (en) 2001-04-26 2004-01-28 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
WO2003057128A2 (en) 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
EP3669887A1 (en) 2002-01-18 2020-06-24 Biogen MA Inc. Polyalkylene polymer compounds and uses thereof
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
JP5305135B2 (en) 2008-08-05 2013-10-02 株式会社リコー Lubricant thinning device, and image forming apparatus and process cartridge provided with the same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5616560A (en) * 1991-12-17 1997-04-01 The Procter & Gamble Company Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
US5744153A (en) * 1994-04-08 1998-04-28 Atrix Laboratories, Inc. Liquid delivery compositions
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6156764A (en) * 1996-02-28 2000-12-05 Lts Lohmann Therapie-Systeme Gmbh Morphine and diamorphine salts of anionic non-narcotic analgesics of the substituted carboxylic acid type
US20030082234A1 (en) * 1999-12-22 2003-05-01 Min-Hyo Seo Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018227187A1 (en) * 2017-06-09 2018-12-13 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
US11530240B2 (en) 2017-06-09 2022-12-20 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering

Also Published As

Publication number Publication date
US20130101656A1 (en) 2013-04-25
TW200514581A (en) 2005-05-01
DE602004016995D1 (en) 2008-11-20
JP2007524628A (en) 2007-08-30
US20050048123A1 (en) 2005-03-03
CY1108685T1 (en) 2014-04-09
CA2530136C (en) 2012-10-16
CN1863557B (en) 2010-06-16
PT1635875E (en) 2008-12-09
PL1635875T3 (en) 2009-03-31
US9566336B2 (en) 2017-02-14
ATE410186T1 (en) 2008-10-15
DK1635875T3 (en) 2009-01-12
CN1863557A (en) 2006-11-15
CA2530136A1 (en) 2005-01-13
EP1635875B8 (en) 2008-12-24
EP1635875B1 (en) 2008-10-08
CN101862455A (en) 2010-10-20
EP2044959A1 (en) 2009-04-08
SI1635875T1 (en) 2009-04-30
WO2005002625A2 (en) 2005-01-13
JP5229768B2 (en) 2013-07-03
TWI377958B (en) 2012-12-01
US20140336278A1 (en) 2014-11-13
WO2005002625A3 (en) 2005-04-21
EP1635875A2 (en) 2006-03-22
AR044926A1 (en) 2005-10-12
ES2315680T3 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
US9566336B2 (en) In situ gelling drug delivery system
US20190201324A1 (en) Injectable sustained release delivery devices
EP1635787B1 (en) Bioerodible sustained release drug delivery systems
US20140154321A1 (en) Sustained release delivery devices
US8871241B2 (en) Injectable sustained release delivery devices
Shi et al. Current advances in sustained-release systems for parenteral drug delivery
CA2624088C (en) Sustained release small molecule drug formulation
EP1610765B1 (en) Non-aqueous single phase vehicles and formulations utilizing such vehicles
ES2321505T3 (en) COMPOSITIONS OF MULTIMODAL POLYMER DEPOSIT INJECTABLE AND USE OF THE SAME.
TW200524631A (en) Excipients in drug delivery vehicles
JP2014040479A (en) Injectable sustained release delivery devices having bioerodible matrix core and bioerodible skin
EP3331495B1 (en) Liquid polymer delivery system for extended administration of drugs
ZA200604777B (en) Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
Vhora et al. Parenteral controlled and prolonged drug delivery systems: therapeutic needs and formulation strategies
CN111012734B (en) Drug-loaded reticular in-situ phase-change gel sustained-release system and preparation method thereof
WO2020089942A2 (en) A liquid injectable composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: CONTROL DELIVERY SYSTEMS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SU, DONGLING;ASHTON, PAUL;CHEN, JIANBING;SIGNING DATES FROM 20040811 TO 20040817;REEL/FRAME:024936/0476

Owner name: PSIVIDA INC., MASSACHUSETTS

Free format text: MERGER;ASSIGNOR:CONTROL DELIVERY SYSTEMS, INC.;REEL/FRAME:024936/0885

Effective date: 20051230

AS Assignment

Owner name: PSIVIDA US, INC., MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:PSIVIDA INC.;REEL/FRAME:027640/0065

Effective date: 20080523

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION